Coverage
-
July 25, 2018
Danish insulin maker Novo Nordisk A/S on Wednesday urged a New Jersey federal judge to dismiss a proposed class action accusing it of misleading investors about its financial sustainability amid U.S. market pressures, arguing that the suing investors haven't pointed to any specific misrepresentations knowingly made by company executives.
1 other articles on this case.
View all »